NORCROSS, Ga., Sept. 5, 2012 PRNewswire/ -- RayBiotech, Inc. today announced that the company has established formal compliance in both Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). Particular product lines now manufactured under GMP status include Quantibody, G-, C- and L-Series antibody arrays as well as all ELISA-related products, but the compliance under GMP guidelines will apply to all products developed, manufactured and sold by the company. GLP-compliance will apply to the performance of all biological sample analysis services. Related to this, RayBiotech also announced the recent construction and launch of a new GLP-compliant laboratory that will be dedicated exclusively to the implementation of ELISA and antibody array biomarker analysis services for its clients. These services will be available to the pharmaceutical, biopharmaceutical, biotechnology and non-profit/academic research communities and will include full biochemical and bioinformatics/biostatistics-related analyses.
RayBiotech's President, COO and Co-founder, Rani Huang, commented, "We have always stood behind the quality of our products and services and RayBiotech's recent attainment of both GMP- and GLP-compliance only further validates our high standards. We look forward to developing and manufacturing products as well as providing analytical services under these new stringent guidelines."
About RayBiotech, Inc.
RayBiotech (www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001, RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for high quality and innovative developments in the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University's School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
For More Information:
Rob Burgess, PhD
Director, Business Development
SOURCE RayBiotech, Inc.